We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Oncolytics Biotech

News List

Oncolytics Biotech, Roche, AIO Initiate Gastrointestinal Cancer Trial americanpharmaceuticalreview
November 05, 2020
Oncolytics Biotech® announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO. The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor ...
Oncolytics Biotech Announces First Patient Treated in MUK Eleven Study americanpharmaceuticacreview
September 15, 2017
REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class systemically delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.
Oncolytics Biotech Announces FDA Fast Track for Reolysin americanpharmaceuticalreview
May 09, 2017
Oncolytics Biotech announced the United States Food and Drug Administration (FDA) granted Fast Track designation for Reolysin, the company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer.